MGMT and astrocytoma (excluding glioblastoma): This pattern of effect was mirrored in the CGGA YAP1 survival analysis, where YAP1 mRNA expression was not a significant prognostic marker in the MGMT methylated group (p = 0.399) (Figure 9C); however, low YAP1 mRNA was associated with significantly increased OS in chemotherapy-treated MGMT unmethylated astrocytoma (YAP1 high vs. low median survival: 16.76 mo.